Non-Invasive Cancer Diagnostics Market 2025 to 2034
Non-Invasive Cancer Diagnostics Market 2025 to 2034
Non-Invasive Cancer Diagnostics Market (By Type: Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other; By Product Type: Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis; By Test Type: Urine Test, Imaging Test, Computerized Tomography, Magnetic Resonance Imaging, Nuclear Medicine Scans, X-ray/Mammography, Ultrasound, Spectroscopy; By Application: Blood, Urine, Saliva; By End Users: Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others; By Region: North America, LAMEA, Europe, Asia-Pacific) – Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2035
Customisation Request
Revenue, 2025
USD 173.13 Bn
Forecast Year, 2035
USD 350.78 Bn
CAGR, 2025 - 2035
7.32%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global non-invasive cancer diagnostics market is valued at USD 173.13 billion in 2025 and is projected to reach USD 350.78 billion by 2035, growing at a CAGR of 7.32%, driven by rising demand for early, accurate, and patient-friendly cancer detection solutions.
Non-Invasive Cancer Diagnostics Market Size Analysis
Non-Invasive Cancer Diagnostics Market Size By Type 2025 to 2034 (USD Billion)
| Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Lung Cancer | 6.28 | 6.68 | 7.15 | 7.77 | 8.22 | 8.89 | 9.49 | 10.14 | 11.01 | 11.83 |
| Breast Cancer | 12.41 | 13.36 | 14.27 | 15.34 | 16.49 | 17.65 | 18.91 | 20.41 | 21.79 | 23.46 |
| Solid Tumors | 18.61 | 19.94 | 21.42 | 22.97 | 24.63 | 26.48 | 28.30 | 30.47 | 32.64 | 34.99 |
| Blood Cancer | 24.70 | 26.51 | 28.53 | 30.53 | 32.86 | 35.23 | 37.86 | 40.54 | 43.46 | 46.68 |
| Ovarian Cancer | 30.86 | 33.13 | 35.57 | 38.15 | 40.98 | 43.94 | 47.24 | 50.64 | 54.49 | 58.39 |
| Colorectal Cancer | 37.05 | 39.76 | 42.70 | 45.79 | 49.13 | 52.73 | 56.65 | 60.81 | 65.19 | 69.96 |
| Other | 43.22 | 46.43 | 49.77 | 53.45 | 57.37 | 61.56 | 66.06 | 70.87 | 76.09 | 81.66 |
Non-Invasive Cancer Diagnostics Market Size By Product Type 2025 to 2034 (USD Billion)
| Product Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunochemistry | 11.67 | 12.52 | 13.49 | 14.46 | 15.53 | 16.62 | 17.89 | 19.13 | 20.51 | 21.88 |
| Clinical Microbiology | 23.02 | 24.88 | 26.70 | 28.56 | 30.58 | 32.81 | 35.35 | 37.85 | 40.70 | 43.51 |
| Point of Care Test (POCT) | 34.69 | 37.09 | 39.75 | 42.86 | 45.87 | 49.23 | 52.77 | 56.64 | 60.83 | 65.50 |
| Hematology | 46.06 | 49.54 | 53.08 | 56.93 | 61.26 | 65.81 | 70.50 | 75.54 | 81.21 | 87.06 |
| Hemostasis | 57.70 | 61.78 | 66.39 | 71.19 | 76.42 | 82.01 | 88.01 | 94.72 | 101.41 | 109.00 |
Non-Invasive Cancer Diagnostics Market Size By Test Type 2025 to 2034 (USD Billion)
| Test Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Urine Test | 4.87 | 5.16 | 5.61 | 6.02 | 6.48 | 6.87 | 7.46 | 7.90 | 8.48 | 9.21 |
| Imaging Test | 9.65 | 10.37 | 11.13 | 11.95 | 12.74 | 13.70 | 14.78 | 15.79 | 17.05 | 18.19 |
| Computerized Tomography | 14.47 | 15.46 | 16.60 | 17.85 | 19.22 | 20.58 | 22.10 | 23.71 | 25.44 | 27.32 |
| Magnetic Resonance Imaging | 19.21 | 20.64 | 22.12 | 23.77 | 25.51 | 27.35 | 29.44 | 31.53 | 33.92 | 36.33 |
| Nuclear Medicine Scans | 24.02 | 25.82 | 27.72 | 29.66 | 31.93 | 34.26 | 36.67 | 39.49 | 42.33 | 45.37 |
| X-ray/Mammography | 28.86 | 31.00 | 33.26 | 35.64 | 38.20 | 41.07 | 43.99 | 47.24 | 50.66 | 54.43 |
| Ultrasound | 33.62 | 36.11 | 38.71 | 41.56 | 44.66 | 47.89 | 51.38 | 55.14 | 59.18 | 63.50 |
| Spectroscopy | 38.43 | 41.24 | 44.27 | 47.56 | 50.93 | 54.75 | 58.70 | 63.08 | 67.60 | 72.60 |
Non-Invasive Cancer Diagnostics Market Size By Application 2025 to 2034 (USD Billion)
| Application | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Blood | 28.89 | 31.16 | 33.61 | 36.06 | 38.61 | 41.09 | 44.07 | 47.85 | 50.94 | 55.08 |
| Urine | 57.76 | 61.94 | 66.26 | 71.02 | 76.59 | 82.27 | 88.03 | 94.41 | 101.51 | 108.53 |
| Saliva | 86.48 | 92.70 | 99.53 | 106.92 | 114.46 | 123.11 | 132.42 | 141.63 | 152.21 | 163.36 |
Non-Invasive Cancer Diagnostics Market Size By End Users 2025 to 2034 (USD Billion)
| End Users | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hospital and Clinics | 17.34 | 18.62 | 20.21 | 21.50 | 22.95 | 24.71 | 26.66 | 28.59 | 30.57 | 32.57 |
| Diagnostic Centers | 34.60 | 37.13 | 39.80 | 42.85 | 45.99 | 49.45 | 52.81 | 56.95 | 60.83 | 65.71 |
| Ambulatory care | 51.94 | 55.91 | 59.80 | 64.08 | 68.79 | 73.94 | 79.48 | 84.98 | 91.40 | 97.96 |
| Others | 69.25 | 74.14 | 79.60 | 85.58 | 91.94 | 98.38 | 105.57 | 113.36 | 121.85 | 130.72 |
Non-Invasive Cancer Diagnostics Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 17.54 | 18.53 | 20.20 | 21.61 | 23.12 | 24.87 | 26.54 | 28.67 | 30.52 | 32.68 |
| LAMEA | 34.56 | 37.16 | 39.89 | 42.86 | 46.00 | 49.15 | 53.08 | 56.63 | 61.09 | 65.39 |
| Europe | 51.93 | 55.73 | 59.63 | 63.92 | 68.80 | 73.97 | 79.28 | 85.19 | 91.17 | 98.05 |
| Asia-Pacific | 69.09 | 74.39 | 79.69 | 85.61 | 91.75 | 98.49 | 105.62 | 113.39 | 121.88 | 130.84 |
Non-Invasive Cancer Diagnostics Market Size to Hit USD 350.78 Billion by 2035
The global non-invasive cancer diagnostics market size is calculated at USD 173.13 billion in 2025 and is predicted to attain around USD 350.78 billion by 2035 with a expanding at a CAGR of 7.32%.
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
